The Bioinformatics Partnering Terms and Agreements report provides a comprehensive understanding and unprecedented access to the bioinformatics accord entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the vaccine technology.

These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals termsprovides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seekingdetails of the payments clauses, the devil is in the detail in terms of how payments aretriggered – contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual bioinformatics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Chapter 1 gives an introduction to the report,while chapter 2 is an overview of the trends in bioinformatics dealmaking since2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listedby headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a linkprovides online access to the contract.

Chapter 4 reveals a comprehensive listing of the top 50 bigpharma companies with abrief summary followed by a comprehensive listing of bioinformatics deals as well as contract documents available in the public domain. Where available, each deal title linksvia Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 gives readers a comprehensive and detailed review of bioinformatics partneringdeals signed and announced since 2007, where a contract document is available in the public domain.

It includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007.

This report teaches a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.